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ABSTRACT 
 
Although CEBPA double-mutated (CEBPA
DM
) acute myeloid leukemia is considered to be 
favorable-risk disease, relapse remains a major cause of treatment failure. Most 
CEBPA
DM
 patients have a classic biallelic mutant combination with an N-terminal 
mutation leading to production of p30 protein plus a C-terminal loss-of-function in-
frame indel mutation (CEBPA
Classic-DM
), but approximately one-third of cases have one or 
more non-classic mutations, with diverse combinations reported, and there is little 
information on the consequences of such mutants. We evaluated outcome in a cohort of 
104 CEBPA
DM
 patients, 79 CEBPA
Classic-DM
 and 25 with non-classic mutants, and found 
that the latter may have poorer survival (5-year overall survival 64% versus 46%, 
P=0.05), particularly post-relapse (41% versus 0%, P=0.02). However, for this analysis, 
all non-classic cases were grouped together, irrespective of mutant combination. As 
CEBPA
DM
 cases have been reported to be hypermethylated, we used methylation 
profiling to assess whether this could segregate the different mutants. We developed a 
CEBPA
Classic-DM
 methylation signature from a preliminary cohort of 10 CEBPA
DM
 
(including 8 CEBPA
Classic-DM
) and 30 CEBPA wild-type (CEBPA
WT
) samples, and 
independently validated the signature in 17 CEBPA
Classic-DM
 cases. Assessment of the 
signature in 16 CEBPA
DM
 cases with different non-classic mutant combinations showed 
that only 31% had a methylation profile equivalent to CEBPA
Classic-DM
 whereas for 69% 
the profile was either intermediate between CEBPA
Classic-DM
 and CEBPA
WT
 or equivalent 
to CEBPA
WT
. These results suggest that CEBPA
DM
 cases with non-classic mutants may be 
functionally different from those with CEBPA
Classic-DM
 mutants and should not 
automatically be included in the same prognostic group. 
(AML12 is registered under ISRCTN17833622 and AML15 under ISRCTN17161961). 
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Introduction 
The CEBPA gene encodes CCAAT/enhancer binding protein-α (C/EBPα), a basic leucine 
zipper (bZIP) transcription factor that is essential for hematopoietic stem cell regulation 
and myeloid development.
1,2
 The gene is mutated in approximately 8% of acute myeloid 
leukemia (AML) patients with intermediate-risk cytogenetics, and presence of biallelic 
double mutations (CEBPA
DM
) in the absence of a FLT3 internal tandem duplication 
(FLT3
ITD
) is associated with a favorable prognosis.
3-9
 In the current risk-adapted therapy 
strategies for AML,
10-12
 these patients are classified as good-risk and therefore not 
usually considered for consolidation of first remission by allogeneic transplantation.
11,13
  
 
Mutations occur throughout the single exon gene but predominate at the N and C 
termini.
14
 N-terminal mutations are nearly always frameshift or nonsense mutations 
causing increased translation from an internal ATG start site and production of a 
truncated p30 protein that retains the same reading-frame as the full-length p42 protein 
but lacks the first transactivation domain (TAD1). The most common C-terminal 
mutations are in-frame indels in the bZIP DNA binding domain (DBD) or leucine zipper 
domain (LZD) that lead to loss of the ability to bind to DNA or dimerize, classified here 
as C-terminal loss-of-function (C-LOF). However, many other mutations have also been 
reported, including missense mutations in the DBD or LZD, missense mutations and in-
frame indels in the mid-region, and frameshift or nonsense mutations in the mid-region 
or C-terminus. Some also present as homozygous alterations due to chromosome 19 
uniparental disomy.
15,16
 The most common combination of mutations is an N-terminal 
frameshift on one allele plus a C-terminal in-frame indel on the other allele that together 
are predicted to lead to complete loss of normal p42 C/EBPα activity,
14
 hereafter called 
the classic CEBPA
DM
 combination (CEBPA
Classic-DM
). This combination was identified in 
204 of 305 CEBPA
DM
 cases (67%) with defined mutants reported in six studies 
containing ≥20 CEBPA
DM
 cases.
3,6,8,17-19
 The remaining 101 cases had multiple different 
mutant combinations with diverse consequences; 54 (18% of total CEBPA
DM
) would be 
predicted to produce just p30 due to the presence of a mid-region or C-terminal 
truncation, 12 (4%) would only produce a classic C-LOF protein, 19 (6%) p30 plus a C-
terminal missense mutant, 5 (2%) just a C-missense mutant and 11 (4%) other mutant 
combinations. 
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Understanding the consequence of the different types of CEBPA
DM
 mutants is needed as 
this may impact on clinical outcome, but there is limited information available on the 
specific mutations. CEBPA
DM
 cases have gene expression profiles that are significantly 
different from single-mutated (CEBPA
SM
) and wild-type (CEBPA
WT
) cases.
3,7
 However, 
recent data suggests that CEBPA
DM
 cases with non-classic combinations may not always 
cluster with other CEBPA
DM
 cases,
7,20
 with three of seven such cases classified as 
negative for the CEBPA
DM
 expression profile in one report.
20
 Furthermore, genotype 
stratification according to expression profiling may be confounded by CEBPA
WT
 cases 
with completely silenced CEBPA expression (CEBPA
SIL
) due to methylation of the CEBPA 
promoter as these cases cluster together with CEBPA
DM
 cases.
21
 CEBPA
DM
 cases also form 
distinct epigenetic clusters with a markedly hypermethylated profile,
22,23
 but although 
CEBPA
SIL
 cases also have a hypermethylated profile, this segregates from the CEBPA
DM
 
cluster and, of note, they appear to be associated with a biologically distinct subtype of 
AML with a poor prognosis.
21,22,24
 Potential methylation differences according to the 
underlying combination of CEBPA mutants, however, have not been reported.  
 
In order to investigate potential differences between CEBPA
DM
 mutant combinations, we 
evaluated clinical outcome in 104 CEBPA
DM
 cases, 79 CEBPA
Classic-DM
 and 25 with non-
classic mutants, and observed that the non-classic cases may have a lower overall 
survival (OS). However, the number of cases was relatively small and all cases with a 
non-classic mutant were included in this group, irrespective of the mutant type. We 
therefore investigated whether methylation profiling of samples from double-mutated 
patients could assist in segregating the different mutant combinations.  
 
Methods 
Patient cohorts 
The patients investigated were younger adults entered into the UK MRC AML10, AML12 
and AML15 trials. Informed patient consent was obtained in accordance with the 
Declaration of Helsinki, and ethical approval for tissue use from the Wales Research 
Ethics Committee 3. Clinical outcome was evaluated in 104 CEBPA
DM
 patients, all <60 
years of age, and methylation profiling was performed on 135 patients, 132 (98%) of 
them <60 years of age (Supplementary Figure S1). Selected tests were performed on a 
further 82 samples with specific cytogenetic and molecular abnormalities. 
 6
  
 Therapy, clinical end points and statistical methods 
Details of clinical protocols, end points and statistical methods are defined in the 
Supplementary Material. 
 
Methylation arrays and data processing 
DNA was bisulfite-converted using the EZ DNA Methylation-Gold Kit (Zymo Research, 
California, USA) and random samples checked by methylation-specific PCR to ensure 
efficient conversion (see Supplementary Material). Methylation profiling was performed 
using the Illumina Infinium HumanMethylation27 (n=40, cohort 1) and 
HumanMethylation450 (n=95, cohort 2) BeadChip arrays (Illumina Inc, California, USA). 
Details of data processing are given in the Supplemental Material. Derived beta values 
were expressed as the percentage methylation at a given CpG probe. Selected CpG sites 
were further analyzed using pyrosequencing assays (see Supplementary Material).  
 
Unsupervised analysis of patient methylation profiles 
In a given sample, probes were defined as methylated if the beta value was >0.3, 
unmethylated if ≤0.3.
25
 Samples were clustered based on their beta values at probes 
displaying significant variation (variable probes) as previously defined.
25,26
 They were 
defined as variable if methylated in ≥1 sample(s) plus unmethylated in ≥1 sample(s). 
CpG islands (CGIs) were located as previously defined;
27
 their methylation levels were 
derived by calculating the mean beta value of probes at these locations. Hierarchical 
clustering was performed using the Euclidian distance of beta values and Ward 
algorithm in R. 
 
Derivation and analysis of CEBPA signature 
A methylation signature of CEBPA genotype was derived from variably methylated CpGs 
in cohort 1. Signature CpGs were selected as the top 25 ranked probes based on the 
mean rank of P values of Wilcoxon tests and the absolute median difference in beta 
value between CEBPA
Classic-DM
 and CEBPA
WT
 samples. Probes were included in the 
analysis if >90% of samples and ≥2 CEBPA
Classic-DM 
and ≥2 CEBPA
WT
 samples had 
observable data. Methylation signatures of CEBPA
Classic-DM
 and CEBPA
WT
 samples were 
then defined as the median beta values observed at these 25 probes. Samples were 
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scored relative to these signatures by calculating the Euclidian distance between the 
signatures and their profiles at signature probes. 
 
Mutant CEBPA level and confirmation of biallelic status 
Mutant CEBPA
 
level was quantified as previously described
6
 or approximated from the 
sequence chromatogram (average height of ≥5 peaks). Monoallelic/biallelic status was 
investigated by sequencing clones derived from full-length CEBPA amplicons as 
previously described.
6
 
 
RESULTS 
Clinical outcome in CEBPA
DM
 cases according to mutant type 
Of the 104 CEBPA
DM
 cases evaluated, 79 had classic and 25 had non-classic mutants 
(Table 1, Supplementary Table S1). The latter included 4 patients predicted to produce 
p30 plus a C-terminal missense mutant, 8 with combinations predicted to produce just 
p30, and 13 with different combinations predicted to produce just a C-LOF protein. 
There was no difference in the baseline characteristics between the classic and non-
classic cases, including white cell count, sex, WHO performance status and AML type (de 
novo or secondary), although the non-classic cases were older (median 35 versus 47 
years, P=0.001) (Supplementary Table S2). All classic cases had intermediate-risk 
cytogenetics compared to 89% of the non-classic cases (P=0.05). There was no 
significant difference in the incidence of FLT3
ITD
, NPM1, IDH1, WT1, TET2 and GATA2 
mutations between the groups, although the non-classic cases had more IDH2 mutations 
(1% versus 20%, P=0.003; all IDH2
R140Q
) and DNMT3A mutations (3% versus 16%, 
P=0.03). Median follow-up was 9.5 years (range, 0.1-22 years). Neither the proportion of 
transplanted patients, the type of transplant nor the stage of transplantation differed 
between the groups (Supplementary Table S2). 
 
CEBPA
Classic-DM
 cases had a slightly higher but statistically non-significantly different 
complete remission (CR) rate to non-classic cases (95% versus 88%, P=0.2) (Table 2). In 
univariate analysis, there was no significant difference in relapse-free survival or 
relapse rate (RR). However, there was a trend towards a lower OS in the non-classic 
cases (64% versus 46% at 5 years, P=0.05) (Figure 1A), which was largely due to the 
worse outcome post-relapse in the non-classic cases. The proportion of relapsing 
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patients who achieved a second remission did not differ between the groups (61% 
versus 55%), but 5-year survival post-relapse was 41% versus 0% (P=0.02) (Figure 1B), 
and 59% versus 0% from second remission (P=0.004) (Figure 1C). The survival 
differences were not, however, statistically different in multivariate analysis (Table 2), 
but this is not surprising given the small group sizes. Although the significantly higher 
proportion of DNMT3A-mutated cases in the non-classic group could have contributed 
to their worse outcome, as both these mutations and FLT3
ITD
 adversely impact on the 
favorable outcome associated with CEBPA
DM
 AML,
6,28
 the trend towards a lower OS in 
the non-classic cases was still present when patients with these mutations were 
excluded (70% versus 53%; Hazard ratio 1.95, 95% confidence intervals 0.95-4.01; 
P=0.08) (Figure 1D).  
 
Development of a CEBPA
Classic-DM
 methylation signature 
The clinical evaluation grouped all non-classic cases together in order to obtain an 
adequate number of patients for analysis, but this cohort therefore included patients 
with many mutant combinations predicted to have differing functional consequences. In 
order to explore potential methods for discriminating between these combinations, we 
investigated the impact of mutant type on methylation profiles. A preliminary cohort of 
samples from 40 normal karyotype (NK) FLT3
WT
NPM1
WT
 patients were investigated 
using the Illumina Infinium HumanMethylation27 array; 10 were CEBPA
DM
 and 30 were 
CEBPA
WT
 (Methylation cohort 1, Table 1), approximating the relative proportions of 
such cases in NK FLT3
WT
NPM1
WT
 patients in our earlier study.
6
 The array data was 
validated by pyrosequencing assays at four differentially methylated CpG sites 
(Supplementary Figure S2). Most CpG sites analyzed showed little variation in 
methylation levels across the whole cohort, but unsupervised cluster analysis according 
to levels of the most variably methylated probes revealed two main clusters. All 10 
CEBPA
DM
 samples, including two non-classic cases, fell in the cluster of 16 samples with 
significantly higher levels of mean CGI methylation (Figure 2A), and the mean level of 
CGI methylation was significantly different between CEBPA
Classic-DM
 and CEBPA
WT
 
samples (Figure 2B).  
 
A supervised approach was then used to create CEBPA
Classic-DM
 and CEBPA
WT
 methylation 
signatures based on the 25 most differentially methylated sites between the CEBPA
Classic-
 9
DM
 and CEBPA
WT
 samples (Figure 2C, Supplementary Table S3). Two distance scores 
were calculated for each sample based on the Euclidian distance between their 
methylation levels at these signature probes and the median profile of the CEBPA
Classic-DM
 
and CEBPA
WT
 samples. This confirmed that, when assessed according to their distance 
scores, the CEBPA
Classic-DM
 samples formed a distinct group that clearly separated from 
the CEBPA
WT 
samples (Figure 3A).  
 
The CEBPA
Classic-DM
 methylation signature was validated with samples from a further 17 
CEBPA
Classic-DM
 and 26 CEBPA
WT
 cases (Methylation cohort 2, Table 1) using the 
HumanMethylation450 array. Sixteen of the 17 CEBPA
Classic-DM
 cases (94%) fell in the 
same cluster in unsupervised analysis, with a relatively more hypermethylated profile, 
and all CEBPA
WT
 cases fell in the hypomethylated cluster (Supplementary Figure S3). 
Using supervised analysis according to the derived CEBPA
Classic-DM
 and CEBPA
WT
 
signatures, the same 16 CEBPA
DM
 cases had a methylation profile that was closest to the 
CEBPA
Classic-DM
 signature with a wide difference between the two signatures (Figures 3B, 
4), indicating that their profile was equivalent to the CEBPA
Classic-DM
 cases in cohort 1. 
Further analysis of the one CEBPA
Classic-DM
 case that fell closer to the CEBPA
WT 
group 
indicated that the mutations were biallelic but only approximately half of the cells in the 
sample carried mutations, mean mutant level 28% for the pair, which was the lowest 
mean level of all 25 CEBPA
Classic-DM 
cases (median 44%; range, 28%-50%). The 
methylation profile of this case could therefore have been affected by the presence of a 
significant proportion of non-leukemic cells and it was excluded from further analyses. 
Using the distance scores (mean±2SD) for CEBPA
Classic-DM
 cases in cohort 1, tests showed 
that these scores classified CEBPA
Classic-DM
 and CEBPA
WT
 genotypes in the second cohort 
with 95% accuracy, 88% sensitivity and 100% specificity. The distance scores of the 24 
CEBPA
Classic-DM
 cases from the combined cohorts were then used to define a CEBPA
Classic-
DM
 quadrant that segregated all CEBPA
Classic-DM
 cases from CEBPA
WT
 cases (Figure 3C). 
 
Investigation of the CEBPA
Classic-DM
 methylation signature in other good-risk 
patients 
In order to examine whether the CEBPA
Classic-DM
 methylation signature could simply 
reflect ‘good-risk’ disease or be due to a lack of C/EBPα expression, methylation levels at 
three differentially methylated CpG sites from the signature were quantified by 
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pyrosequencing using samples from 21 patients with inv(16) and 19 with t(8;21), both 
associated with downregulated C/EBPα expression,29-31 and 42 with NPM1MUTFLT3WT. 
KHNYN and VAMP5 were more hypermethylated in the CEBPA
Classic-DM
 signature, LY9 
more hypomethylated. Each subgroup differed significantly from the 24 CEBPA
Classic-DM
 
cases at two of the three sites (Supplementary Figure S4). A composite methylation 
score was calculated for each sample; it was statistically significantly different from the 
CEBPA
Classic-DM
 cases for all three subgroups (Figure 5), indicating that the methylation 
profile was a distinct feature of the mutant proteins that lead to total loss of normal 
C/EBPα function rather than absence of C/EBPα per se. 
 
Investigation of non-classic CEBPA
DM
 and CEBPA
SM
 mutants 
Having established that CEBPA
Classic-DM
 cases have a methylation profile that is distinct 
from CEBPA
WT
 cases, profiles of 14 CEBPA
DM
 cases with a variety of different non-classic 
combinations were investigated using the HumanMethylation450 array (Methylation 
cohort 2, Table 1). On unsupervised analysis, nine (64%) were hypermethylated and five 
(36%) hypomethylated (Supplementary Figure S3). To assess their impact on the CEBPA 
methylation signatures, these 14 cases and the two non-classic cases from the initial 
cohort were considered according to the predicted functional consequence of the 
combination.  
 
Six cases were predicted to produce just p30 protein, with a classic N plus null mutant 
(mid-region or C-terminal frameshift/nonsense) combination. Only one fulfilled the 
CEBPA
Classic-DM
 criteria; four fell outside this quadrant but were still distinct from 
CEBPA
WT
 cases, and one grouped with the CEBPA
WT
 cases (Figure 6A). Three cases were 
predicted to just give rise to classic C-LOF proteins without p30 (two homozygous 
classic C, one compound heterozygous with a classic C plus C-frameshift combination). 
Two fulfilled the CEBPA
Classic-DM
 criteria and one was intermediate between CEBPA
Classic-
DM
 and CEBPA
WT
. The seven cases with missense mutations were also highly variable. 
Three had a classic N plus C-missense combination; none fulfilled the CEBPA
Classic-DM
 
criteria, two were intermediate between the signatures and one grouped with CEBPA
WT
 
cases. Mutant levels were indicative of 80% or more mutated cells in all three cases; two 
were biallelic by cloning but no full-length amplicons could be obtained in one case. 
Similarly, only one of the three homozygous C-missense cases fell in the CEBPA
Classic-DM
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quadrant, the other two were equivalent to CEBPA
WT
 cases. The remaining case was 
compound heterozygous with a classic C and C-missense combination, and did fulfil the 
CEBPA
Classic-DM
 criteria.  
 
These results suggest that the functional consequence of double-mutated cases 
producing at least one non-classic mutant protein can be highly variable and difficult to 
predict. Of note, when outcome was assessed in the non-classic cases according to their 
methylation profile, there was a suggestion that those that fulfilled the CEBPA
Classic-DM
 
methylation criteria were less likely to relapse, with only 1 of 4 cases (25%) relapsing 
compared to 7 of 10 cases (70%) that fell outside the CEBPA
Classic-DM
 quadrant (5-year RR 
25% versus 54% respectively). These numbers were too small for meaningful statistical 
analysis, and the results do not necessarily indicate a causal link between the 
methylation pattern and outcome. They do suggest, however, that the methylation 
pattern could be a useful biomarker, and thereby act as a surrogate for response and 
selection of therapy.  
 
Methylation cohort 2 also included 38 CEBPA
SM
 cases with a wide range of classic and 
non-classic mutants (Table 1). On unsupervised analysis, 31 (82%) were in the 
hypomethylated cluster, with no apparent segregation between the CEBPA
SM
 and 
CEBPA
WT
 cases (Supplementary Figure S3). On supervised analysis, all except two cases 
were equivalent to CEBPA
WT
 cases, with no obvious grouping according to the type of 
mutant (Figures 4, 6B). The remaining two cases fell in or close to the CEBPA
Classic-DM
 
quadrant; both had a classic C mutation. It is possible that the CEBPA
WT
 allele had been 
silenced in these cases, but RNA samples were not available to check this. 
 
Discussion 
Molecular genotyping is increasingly used to risk stratify patients with AML, but clinical 
application of this information needs to be accurate and robust for optimal patient 
therapy. This is particularly important for good-risk patients such as those with biallelic 
CEBPA mutations, where the current recommendation is not to proceed to 
transplantation in first remission, as for some patients this could lead to under-
treatment. Identifying those who are at greater risk of relapse and poorer survival may 
therefore guide patient management. Very limited information is available on the impact 
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of the different CEBPA mutations, with all CEBPA
DM
 cases currently being classified as 
good-risk, irrespective of the underlying mutant. However, mutations identified in 
approximately one-third of CEBPA
DM
 patients do not conform to the classic combination 
of N-terminal frameshift or nonsense mutation plus C-terminal in-frame indel. As many 
of the other mutations are unique and of unknown functional consequence, determining 
their significance is challenging, particularly in view of the multiple functions attributed 
to C/EBPα.
1,2
  
 
Although we had access to a database of 2162 patients with known CEBPA genotype and 
available clinical data from three consecutive UK MRC trials of younger adult patients 
with AML, 67% with intermediate-risk cytogenetics, we were still able to evaluate long-
term outcome in a cohort of only 79 CEBPA
Classic-DM
 cases and 25 CEBPA
DM
 cases with at 
least one non-classic mutant. The results suggested that the non-classic cases may have 
a poorer outcome; in particular, none of these cases survived after relapse. These results 
may be influenced by differences in the coincident mutations in the two groups. The 
majority of recurrent mutations with known prognostic significance in AML are 
uncommon in CEBPA
DM
 cases,
32
 and for many of them their impact in this subgroup is 
therefore not well defined. Both FLT3
ITD 
and DNMT3A mutations adversely impact on 
the favorable outcome of CEBPA
DM
 AML.
6,28
 but even when patients with these mutations 
were excluded from the analysis, OS for the non-classic cases was still worse. The 
incidence of GATA2 mutations was non-significantly lower in the non-classic cases, but 
although one study reported that they are associated with better OS,
33
 most studies, 
including our own, observed no difference.
34,35
 There was a non-significantly higher 
incidence of TET2 mutations in the non-classic cases, but their impact is unclear, with 
only one study reported specifically for CEBPA
DM
 AML that showed a worse OS but not 
event-free survival in TET2
MUT
 cases.
33
 Clearly, many more cases would need to be 
analyzed in order to take into account coincident mutations other than FLT3
ITD
 and 
DNMT3A mutations. 
 
A wide range of non-classic mutations was observed and, for the outcome analysis, 
sufficient patient numbers could only be obtained by grouping all the non-classic 
patients together, which precluded evaluation of specific mutant combinations. We 
therefore sought alternative methods of assessment and, as CEBPA
DM
 patients have a 
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distinct hypermethylated profile,
22,23
 investigated whether genome-wide methylation 
profiling could provide information on the more broad-spectrum functional 
consequence of different mutants. We confirmed the relatively hypermethylated profile 
associated with a CEBPA
DM
 genotype in a preliminary cohort and then derived 
methylation signatures for CEBPA
Classic-DM
 and CEBPA
WT
 cases using the 25 most 
differentially methylated CpG sites. These were validated in an independent cohort of 
samples, with 16 of the 17 CEBPA
Classic-DM
 cases studied clearly separating from the 
CEBPA
WT
 cases. The remaining case contained a significant proportion of non-mutated 
cells, which provided indirect evidence that the signatures reflected CEBPA genotype. 
The signatures were a distinct feature of mutant C/EBPα and could not simply be 
attributed to a lack of C/EBPα, as they were not replicated in samples from patients with 
core-binding factor leukemias that are associated with down-regulation of CEBPA 
expression. Presence of at least a minimal level of C/EBPα activity is thought to be 
necessary for the development of leukemia as Cebpa
-/- 
mice with totally absent C/EBPα 
accumulate immature myeloid progenitors but do not develop AML,
36,37
 and AML 
patients have not been reported with mutations leading to complete absence of C/EBPα. 
These results therefore suggest that it is the functionally aberrant C/EBPα protein that 
underlies the hypermethylated profile detected in the CEBPA
DM
 cases. 
 
The CEBPA
Classic-DM
 cases provided a framework for assessing the methylation profiles of 
mutant combinations with at least one non-classic mutant. Only 31% had a methylation 
profile equivalent to CEBPA
Classic-DM
, 25% were equivalent to CEBPA
WT
, and 44% were 
intermediate between the two. Similar heterogeneity has been reported for gene 
expression profiles of non-classic cases, with three of seven such cases segregating from 
cases with classical mutants.
20
 This variability is not surprising considering the diversity 
of the mutant combinations. Although the p30 isoform is thought to play an important 
role in allowing commitment of the leukemic stem cell to the myeloid lineage,
38
 the 
mechanism by which it promotes AML is not clearly defined. It has a lower affinity for 
some C/EBP sites than p42 and induces multiple genes that are not affected by p42,
39-41
 
and this may have influenced the methylation profile. Knock/in mice expressing just N-
terminal mutant developed leukemia but more slowly than the N+C combination.
38,42
 
This presumably reflects the additional influence of an aberrant C-terminally mutated 
protein that might not bind to DNA but can still bind to other C/EBP interacting proteins 
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such as PU.1 and the SWI/SNF complex. Classic C-terminal mutants are associated with 
hyperproliferation due to loss of cell-cycle regulation and a block in myeloid 
differentiation.
43
 Although knock/in mice with classic C mutant alone do develop 
leukemia, it is with slower latency than the N+C and mutant N mice.
42
 Since these 
mutants may still bind and potentially sequester other interacting factors, it has been 
suggested that this could limit the ability of other C/EBPs to rescue the effect of the 
aberrant C/EBPα,
2
 as shown for C/EBPβ in the C/EBPα-deficient situation.44,45 This 
more global cellular impact of the C-terminal mutants may have a greater consequence 
for signaling events downstream of C/EBPα, which may therefore be reflected in the 
methylation profile. 
 
The methylation profiles did not group according to the predicted functional 
consequence of the mutant, whether N- or C-terminally mutated. For example, 
considerable variability was observed for the cases with a C-missense mutation. Of the 
three classic N plus C-missense combinations assayed, one case had a methylation 
profile equivalent to CEBPA
WT
 and two cases had intermediate profiles. Two 
homozygous C-missense cases grouped with CEBPA
WT
 cases, whereas another 
homozygous C-missense case grouped with the CEBPA
Classic-DM
 cases. In the 51 cases 
documented with C-missense mutations in the COSMIC database 
(http://cancer.sanger.ac.uk/cosmic), most mutations are unique, reported in one (n=27, 
53%) or two (n=9, 18%) patients, and only two residues (R297 and R300) are recorded 
as being variably mutated in five patients. Critical amino acids at the bZIP/DNA interface 
have been identified from the C/EBPα crystal structure, but many additional hydrogen 
bonds and van der Waals contacts are implicated in the stabilization of these 
interactions,
46
 and predicting the functional consequence of these mutants is therefore 
difficult.  
 
From a clinical perspective, risk management requires evaluation of all the available 
information, and the data presented here suggests that CEBPA
DM
 patients with a non-
classic mutation should not automatically be included in the same favorable-risk 
prognostic group as CEBPA
Classic-DM
 cases, and that it might be appropriate to consider 
them for allogeneic transplantation in first remission. Ultimately, this can only be 
proven by analysis of clinical trial outcomes and, with the increasing availability of large 
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data sets using targeted next-generation sequencing panels, such analysis may be 
feasible in the future. This will also facilitate a better understanding of the mutational 
background of classic and non-classic CEBPA
DM
 cases and whether there are differences 
that impact on their prognosis. Our studies also raise the possibility that methylation 
profiling may identify those non-classic cases that behave in a similar manner to classic 
mutants, although we cannot directly attribute a causal link between the methylation 
pattern and chemosensitivity, and further studies are required before this is introduced 
into clinical practice.  
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Table 1. CEBPA genotype of investigated cohorts  
 
 CEBPA genotype* n Predicted functional 
consequence 
Clinical cohort 
(n=104) 
CEBPA
 Classic-DM
 
 
Non-classic CEBPA
 DM
 
     Classic N + C-missense 
     Classic N + mid-frameshift 
     Classic N + C-frameshift 
     Homozygous classic N 
     Homozygous classic C 
     Homozygous C-missense 
     Classic C + C-frameshift 
     Classic C + C-missense 
     Mid-frameshift + C-missense 
79 
 
 
4 
5 
2 
1 
4 
3 
4 
1 
1 
p30 + C-LOF 
 
 
p30 + C-LOF 
p30 
p30 
p30 
C-LOF 
C-LOF 
C-LOF 
C-LOF 
C-LOF 
Methylation 
Cohort 1 
(n=40) 
CEBPA
 Classic-DM
 
 
Non-classic CEBPA
 DM
 
     Classic C + C-frameshift 
     Homozygous C-missense 
 
CEBPA
 WT
 
8 
 
 
1 
1 
 
30 
p30 + C-LOF 
 
 
C-LOF 
C-LOF 
 
WT 
Methylation 
Cohort 2 
(n=95) 
CEBPA
 Classic-DM
 
 
Non-classic CEBPA
 DM
 
     Classic N + C-missense 
     Classic N + mid-frameshift 
     Classic N + C-frameshift 
     Homozygous classic C 
     Homozygous C-missense 
     Classic C + C-missense 
 
CEBPA
 SM
 
     Classic N 
     Classic C 
     Mid-indel      
     Mid-frameshift 
     Mid-missense 
     C-frameshift 
     C-missense 
 
CEBPA
 WT
 
17 
 
 
3 
5 
1 
2 
2 
1 
 
 
9  
5 
3 
9 
5 
2 
5 
 
26 
p30 + C-LOF 
 
 
p30 + C-LOF 
p30 
p30 
C-LOF 
C-LOF 
C-LOF 
 
 
p30 + WT 
C-LOF + WT 
UNK + WT 
Null**+ WT 
UNK + WT 
Null** + WT 
C-LOF + WT 
 
WT 
 
*Details of the specific mutations are given in Supplementary Table S1. 
**Mid-region or C-terminal mutants with a truncating frameshift or nonsense mutation 
Abbreviations: C, C-terminal mutation; C-LOF, C-terminal loss-of-function; DM, double 
mutant; indel, in-frame insertion and/or deletion; N, N-terminal mutation; SM, single 
mutant; UNK, unknown; WT, wild-type 
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Table 2. Outcome according to CEBPA
DM
 mutant combination 
 
 
Outcome Classic 
CEBPA
DM 
(n=79) 
Non-classic 
CEBPA
DM
 
(n=25) 
CEBPA
Classic-DM
 vs non-classic CEBPA
DM
 
OR or HR (95% CI), P-value 
Univariate                            Multivariate* 
CR 95% 88%** 3.20 (0.53-19.47); P=0.2 Not evaluable*** 
5 yr OS 64% 46% 1.84 (1.01-3.37), P=0.05 1.44 (0.74-2.79), P =0.3 
5 yr RFS 49% 45% 1.15 (0.61-2.16), P=0.7 1.03 (0.52-2.06), P =0.9 
5 yr RR 41% 77% 1.32 (0.66-2.66), P=0.4 1.09 (0.47-2.55), P =0.8 
 
*Adjusted for age, white blood cell count, WHO performance status, type of leukemia, sex, FLT3 and DNMT3A genotype. 
**Remission status was missing for one patient 
***Insufficient events for analysis 
Abbreviations: CI, confidence intervals; CR, complete remission; DM, double mutant; HR, hazard ratio; OR, odds ratio; OS, overall 
survival; RFS, relapse-free survival; RR, relapse rate 
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Figure Legends 
 
Figure 1. Clinical outcome in CEBPA
DM
 patients according to mutant 
combination. (A) Overall survival in the total cohort of 104 CEBPA
DM
 patients. (B) 
Survival post-relapse in the 39 patients that relapsed. (C) Survival from second 
remission in the 23 relapsed patients who achieved a second remission. (D) Overall 
survival in the total cohort excluding patients with FLT3
ITD
 and DNMT3A mutations. 
 
Figure 2.  Methylation profile of the preliminary cohort of 40 samples. (A) 
Unsupervised cluster analysis of the cohort. Each column represents a patient. Genotype 
is given in the upper panel. Samples were clustered based on their methylation levels at 
7,679 variable probes, and the heatmap in the middle panel shows the variable CpG 
probes located within CpG islands (CGIs). The latter were used to calculate the mean % 
CpG methylation shown in the lower panel; red and blue bars indicate a predominantly 
hyper- or hypo-methylated profile respectively. (B) The mean level CGI methylation for 
CEBPA
WT
 and CEBPA
Classic-DM
 samples. CGI methylation levels were calculated from all 
autosomal CGI probes. ***P<0.001 (Wilcoxon test). (C) Supervised cluster analysis 
showing the derived CEBPA
Classic-DM
 signature on the left and the CEBPA
WT
 signature on 
the right. Samples are ordered according to their level of similarity to the CEBPA
Classic-DM
 
signature using Euclidian distance. The lower panel shows the distance scores indicating 
the distance from the CEBPA
Classic-DM
 (green circles) and CEBPA
WT
 (white circles) 
signatures; the lower the y axis value, the more closely the sample matches that 
particular signature.  
 
Figure 3. Analysis of the methylation profiles of the samples according to their 
distances from the derived CEBPA
Classic-DM
 and CEBPA
WT
 methylation signatures. 
Difference between the distance scores (CEBPA
Classic-DM
 - CEBPA
WT
) compared with the 
distance from the CEBPA
Classic-DM
 (MUT) signature of (A) the preliminary cohort and (B) 
the CEBPA
Classic-DM
 and CEBPA
WT 
cases in the follow-up cohort. (C) Criteria derived for 
CEBPA
Classic-DM
 using mean±2SD of the distance scores of all 24 CEBPA
Classic-DM
 cases.  
 
Figure 4.  Analysis of the follow-up cohort of 95 samples. Supervised analysis 
according to the CEBPA
Classic-DM
 and CEBPA
WT
 methylation signatures. Patient CEBPA 
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genotype is given above the heatmap. The lower panel shows the distance scores 
indicating the distance from the CEBPA
Classic-DM
 (green circles) and CEBPA
WT
 (white 
circles) signatures; the lower the y axis value, the more closely the sample matches that 
particular signature.  
 
Figure 5.  Methylation levels in other good-risk groups compared to the 
CEBPA
Classic-DM
 cases. A composite methylation score was calculated by summing the 
difference between the % methylation for samples and the median for the 24 
CEBPA
Classic-DM
 cases (excluding the outlier) for three differentially methylated CpG sites, 
KHNYN, VAMP5 and LY9. Mean values±95% confidence intervals are shown. The 
CEBPA
Classic-DM
 and CEBPA
WT
 results were beta values from the arrays; results for the 
three comparative groups were obtained by pyrosequencing. Significance refers to 
difference from the CEBPA
Classic-DM
 group (*P≤0.05, **P≤0.01, ***P≤0.001). 
 
Figure 6.  Supervised analysis of CEBPA
DM
 cases with non-classic mutations and 
CEBPA
SM
 cases. Difference between the distance scores (CEBPA
Classic-DM
 - CEBPA
WT
) 
compared with the distance from the CEBPA
Classic-DM
 (MUT) signature for (A) CEBPA
DM
 
cases with a non-classic mutant. (B) CEBPA
SM
 cases. 
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SUPPLEMENTARY	MATERIAL	
	
Therapy,	clinical	end	points	and	statistical	methods	Details	of	the	clinical	protocols	have	been	published	elsewhere.1-3	CR	was	defined	as	a	normocellular	bone	marrow	(BM)	containing	<5%	blasts	and	showing	evidence	of	normal	maturation	of	other	marrow	elements.	Persistence	of	myelodysplastic	features	did	not	preclude	the	diagnosis	of	CR.	OS	was	the	time	from	trial	entry	to	death.	For	patients	achieving	CR,	relapse-free	survival	(RFS)	was	the	time	from	the	date	of	first	CR	to	an	event	(death	in	first	CR	or	relapse)	and	relapse	rate	(RR)	was	the	cumulative	probability	of	relapse,	censoring	at	death	in	CR.			Mantel-Haenszel	and	chi-squared	tests	were	used	to	test	for	differences	in	demographic	and	clinical	data	by	genotype.	Kaplan-Meier	curves	were	constructed	for	survival	data	and	compared	by	means	of	the	log-rank	test.	Surviving	patients	were	censored	on	August	2010	for	AML10	and	AML12,	March	2015	for	AML15.	Median	follow-up	for	survival	was	9.5	years	(range,	0.1-22	years).	Multivariable	Cox	models	were	used	to	analyze	OS,	RFS	and	RR,	adjusting	for	age,	white	cell	count,	WHO	performance	status,	secondary	leukemia	and	trial,	with	additional	variables	of	interest	(CEBPA	mutant	type,	
FLT3ITD	and	DNMT3A	genotype).	Models	were	fitted	using	forward	selection,	with	variables	added	to	the	model	if	they	had	a	P	value,	derived	using	the	deviance	statistic,	of	<0.05.	Odds	ratios	(OR)	or	hazard	ratios	(HR)	and	95%	confidence	intervals	(CI)	are	quoted	for	endpoints.	In	all	cases	a	ratio	of	<1	indicates	benefit.	All	P	values	are	two-tailed.		
	
Bisulfite	conversion	and	methylation-specific	PCR	to	assess	conversion	efficiency	An	aliquot	of	350-500ng	DNA	was	bisulfite-converted	using	the	EZ	DNA	Methylation-Gold	Kit	(Zymo	Research,	California,	USA)	according	to	the	manufacturer’s	instructions	except	that	the	incubation	at	50oC	for	16	hours	included	a	denaturation	step	at	95oC	for	30	seconds	at	the	beginning	of	each	hour.	This	periodic	cycling	has	been	reported	to	improve	conversion	efficiency.4		Several	samples	were	randomly	selected	from	each	converted	batch	and	subjected	to	two	methylation-specific	PCRs	of	the	HLA-B	gene,	one	using	primers	that	would	only	
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amplify	bisulfite-converted	DNA	and	the	other	using	primers	that	would	only	amplify	unconverted	DNA	(see	Table	S5).	For	each	PCR,	1μl	of	converted	DNA	was	added	to	1x	manufacturer’s	buffer,	3mM	MgCl2,	200μM	dNTPs,	25pmols	each	primer	and	1U	GoTaq	polymerase	(Promega)	in	a	total	volume	of	25μl.	An	initial	denaturation	step	at	95oC	for	6	minutes	was	followed	by	36	cycles	of	PCR,	each	of	94oC	for	30	seconds,	annealing	temperature	for	30	seconds	and	72oC	for	30	seconds,	with	2	cycles	at	annealing	temperatures	of	60oC,	59oC	and	58oC,	then	30	cycles	at	57oC,	followed	by	a	final	extension	step	of	72oC	for	15	minutes.	PCR	products	were	run	on	a	2%	agarose	gel.	Samples	were	considered	to	be	successfully	bisulfite-converted	if	they	had	a	PCR	product	with	the	primers	for	the	bisulfite-converted	DNA	but	no	product	with	the	primers	for	the	unconverted	DNA.		
Data	processing	for	the	methylation	arrays		Data	from	the	Illumina	Infinium	HumanMethylation27	and	HumanMethylation450	BeadChip	arrays	(Illumina	Inc,	California,	USA)	were	exported	from	Illumina’s	genome	studio	and	subsequent	analysis	was	performed	using	R.	Beta	values	were	used	as	a	measure	of	the	methylation	level	at	a	given	CpG	probe	as	derived	from	the	intensity	of	the	methylated	(Imeth),	and	unmethylated	(Iunmeth)	allele	probes	(Imeth	/(Imeth	+	Iunmeth).	The	data	from	450K	arrays	was	normalized	to	correct	for	systematic	biases	between	the	two	types	of	probes	present	on	these	arrays	as	described.5	Beta	values	were	then	filtered	to	remove	unreliable	data	points	based	on	the	detection	P	value	from	the	Infinium	arrays	(threshold	0.01)	by	setting	their	values	to	NA.	Finally,	probes	displaying	gender-specific	biases	were	filtered	out,	defining	them	as	those	with	Wilcoxon	tests	P	values	<0.05	between	genders.	This	resulted	in	the	exclusion	of	1,362	probes	from	the	first	cohort	(Infinium	27K	array)	and	56,356	probes	from	the	follow-up	cohort	(Infinium	450K	array).	Beta	values	were	converted	to	percentage	methylation	levels	by	multiplying	by	100.			
Pyrosequencing	assays	Pyrosequencing	assays	to	interrogate	specific	CpG	sites	were	designed	using	the	PyroMark	Assay	Design	Software	2.0	(Qiagen,	Crawley,	UK).	For	each	PCR,	25ng	DNA	was	added	to	1x	manufacturer’s	buffer,	3.5mM	MgCl2,	200μM	dNTPs,	0.2μM	primers,	one	biotin-labeled	and	one	unlabeled,	and	1.25U	GoTaq	polymerase	(Promega)	in	a	total	
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volume	of	20μl.	The	mixes	were	denatured	at	95oC	for	5	minutes	and	then	subjected	to	50	cycles	of	amplification	using	primers	and	annealing	temperatures	as	specified	in	Table	S5.	Products	were	sequenced	on	a	PyroMark	MD	system,	(Qiagen)	using	PyroMark	Q96	reagents	and	protocols	and	the	appropriate	primer	as	specified	in	Table	S5.	All	samples	were	assayed	in	duplicate	and	the	mean	methylation	level	expressed	as	a	percentage	of	the	total	alleles	for	a	particular	site.	For	each	assay,	titration	curves	were	created	using	standards	containing	0%,	10%,	25%,	50%,	75%,	90%	and	100%	methylated	DNA,	prepared	from	bisulfite-converted	fully	methylated	and	unmethylated	DNA	(Epitect	Control	DNA	set,	Qiagen),	to	check	for	accuracy	and	sensitivity.			
REFERENCES		1.	 Hann	IM,	Stevens	RF,	Goldstone	AH,	et	al.	Randomized	comparison	of	DAT	versus	ADE	as	induction	chemotherapy	in	children	and	younger	adults	with	acute	myeloid	leukemia.	Results	of	the	Medical	Research	Council's	10th	AML	trial	(MRC	AML10).	Adult	and	Childhood	Leukaemia	Working	Parties	of	the	Medical	Research	Council.	Blood.	1997;89(7):2311-2318.	2.	 Burnett	AK,	Hills	RK,	Milligan	DW,	et	al.	Attempts	to	optimize	induction	and	consolidation	treatment	in	acute	myeloid	leukemia:	results	of	the	MRC	AML12	trial.	J	Clin	Oncol.	2010;28(4):586-595.	3.	 Burnett	AK,	Russell	NH,	Hills	RK,	et	al.	Optimization	of	chemotherapy	for	younger	patients	with	acute	myeloid	leukemia:	results	of	the	medical	research	council	AML15	trial.	J	Clin	Oncol.	2013;31(27):3360-3368.	4.	 Thirlwell	C,	Eymard	M,	Feber	A,	et	al.	Genome-wide	DNA	methylation	analysis	of	archival	formalin-fixed	paraffin-embedded	tissue	using	the	Illumina	Infinium	HumanMethylation27	BeadChip.	Methods.	2010;52(3):248-254.	5.	 Dedeurwaerder	S,	Defrance	M,	Calonne	E,	Denis	H,	Sotiriou	C,	Fuks	F.	Evaluation	of	the	Infinium	Methylation	450K	technology.	Epigenomics.	2011;3(6):771-784.			
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SUPPLEMENTARY	TABLES	
	
Table	S1.	 Full	details	of	CEBPA	mutations	in	the	patients	studied	
	
Coh Genotype Mutant 1 Mutant 2 Type of mutation Predicted proteins 
Clin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classic DM p.H18fs 
p.H18fs 
p.S21fs 
p.S21fs 
p.P23fs 
p.P23fs 
p.P23fs 
p.H24fs 
p.H24fs 
p.H24fs 
p.H24fs 
p.H24fs 
p.H24fs 
p.H24fs 
p.A29fs 
p.A30fs 
p.F31fs 
p.F33fs 
p.R35fs 
p.G36fs 
p.G36fs 
p.G36fs 
p.G36fs 
p.G36fs 
p.A37fs 
p.G38fs 
p.G38fs 
p.A40fs 
p.P43fs 
p.P49fs 
p.E50fs 
p.G53fs 
p.G54fs 
p.I55fs 
p.C56fs 
p.E59fs 
p.E59fs 
p.I62fs 
p.I62fs 
p.I62fs 
p.A66fs 
p.A66fs 
p.Y67X 
p.I68fs 
p.I68fs 
p.A72fs 
p.F73fs 
p.F77fs 
p.L78fs 
p.L78fs 
p.L78fs 
p.A79fs 
p.F82fs 
p.Q83fs 
p.Q83fs 
p.Q83fs 
p.Q83fs 
p.H84fs 
p.Q88fs 
p.A91fs 
p.V95fs 
p.G96fs 
p.G96fs 
p.G96fs 
p.T98fs 
p.G99fs 
p.G101fs 
p.F106fs 
p.F106fs 
p.D107fs 
p.D107X 
p.D107fs 
p.Y108X 
p.G110fs 
p.E309del 
p.Q312del 
p.N307_Q312del 
T310dup 
K304_Q305insL 
p.N307_E309delinsK 
p.L315_E316insT 
p.K304_Q305insL 
p.K304_R306dup 
p.V308dup 
p.Q311_Q312insL 
p.Q311_Q312insL 
p.K313Nins14 
p.K313_V314insQK 
p.L315dup 
p.Q312Hins15 
p.K313dup 
p.K326delins23 
p.E309dup 
p.R297_Q311dup 
p.D301_L315dup 
p.K304_Q312dup 
p.R306_N307insKQR 
p.E309delinsKTQ 
p.E309_T310insSQ 
p.T310_Q312delinsK 
p.D320_N321ins16 
p.E309_L317dup 
p.Q312dup 
p.Q305_E316dup 
p.V314_L315ins13 
p.K313dup 
p.Q305_R306insQQ 
p.Q312_K313ins12 
p.K302_R306dup 
p.E309dup 
p.T318_S319insI 
p.E309delinsAQ 
p.Q312dup 
p.E329_Q330ins35 
p.T310_Q311insP 
p.E316_L317insR 
p.R297_V308dup 
p.R306_N307insRR 
p.K313dup 
p.K302_E309dup 
p.R306dup 
p.R306_Q311del 
p.R300_L324dupinsR 
p.V308_R327dup 
p.K313dup 
p.Q312dup 
p.K304_V308dup 
p.R300_Q312dup 
p.Q312_K313insE 
p.K313dup 
p.K313dup 
p.K302_K304dup 
p.K304_Q305insL 
p.S319delinsRL 
p.V308I+Q312dup 
p.T310_Q311ins10 
p.K313dup 
p.L317_T318insM 
p.T310dup 
p.K304_Q305insL 
p.Q312dup 
p.D301_V308dup 
p.K302_R306dup 
p.S299_T318dup 
p.D301del 
p.E309delinsGQ 
p.E309_T310insK 
p.Q312dup 
Classic N + C p30 + C-LOF 
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Clin 
(cont) 
p.G110fs 
p.P112fs 
p.A113fs 
p.G114fs 
p.G114fs 
p.Q312dup 
p.K304_Q305insL 
p.L315_E316insQ 
p.Q312dup 
p.K313dup 
 Non-classic DM p.A44fs 
p.I68fs 
p.L78fs 
p.A79fs 
p.A295P 
p.R297P 
p.R300P 
p.Q305P 
Classic N + C-missense 
Classic N + C-missense 
Classic N + C-missense 
Classic N + C-missense 
p30 + C-LOF 
  p.H24fs 
p.H24fs 
p.G36fs 
p.G38fs 
p.G54fs 
p.E89fs (Hom) 
p.V95fs 
p.P121fs 
p.Q209fs 
p.G223fs 
p.Y181X 
p.K313fs 
p.E167fs 
 
p.A238fs 
p.Q312X 
Classic N + mid-frameshift 
Classic N + mid-frameshift 
Classic N + mid-frameshift 
Classic N + C-frameshift 
Classic N + mid-frameshift 
Classic N 
Classic N + mid-frameshift 
Classic N + C-frameshift 
p30 + null 
  p.L178fs 
p.R300_D301selinsQN (Hom) 
p.R306_V314dup 
p.Q312delinsPK 
p.K313dup 
p.K313dup 
p.K313dup (Hom) 
p.V314G (Hom) 
p.E316_L317insR 
p.E316_R325dup (Hom) 
p.L317Q (Hom) 
p.L317_K326dup (Hom) 
p.N321S (Hom) 
p.K276R 
 
p.N321S 
p.R343fs 
p.R343fs 
p.S349fs 
 
 
p.R343fs 
Mid-frameshift + C-missense 
Classic C 
Classic C + C-missense 
Classic C + C-frameshift 
Classic C + C-frameshift 
Classic C + C-frameshift 
Classic C 
C-missense 
Classic C + C-frameshift 
Classic C 
C-missense 
Classic C 
C-missense 
C-LOF 
M1 Classic DM p.H24fs 
p.G54fs 
p.A66fs 
p.I68fs 
p.L78fs 
p.H84fs 
p.A91fs 
p.G114fs 
p.Q311_Q312insL 
p.Q305_R306insQQ 
p.E316_L317insR 
p.R306_N307insRR 
p.E309_V328dup 
p.K302_K304dup 
p.S319delinsRL 
p.Q312dup 
Classic N + C p30 + C-LOF 
Non-classic DM p.K313dup 
p.V314G (Hom) 
p.R343fs Classic C + C-frameshift 
C-missense 
C-LOF 
M2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classic DM p.P23fs 
p.H24fs 
p.H24fs 
p.H24fs 
p.A40fs 
p.P43fs 
p.E50fs 
p.I55fs 
p.E59fs 
p.Y67X 
p.A72fs 
p.A79fs 
p.Q88fs 
p.G96fs 
p.D107fs 
p.P112fs 
p.A113fs 
p.N307_E309delinsK 
p.K304_Q305insL 
p.Q311_Q312insL 
p.K313Nins14 
p.E309_L317dup 
p.Q312dup 
p.V314_L315ins13 
p.Q312_K313ins12 
p.E309dup 
p.R297_V308dup 
p.K302_E309dup 
p.Q312dup 
p.K304_Q305insL 
p.T310_Q311ins10 
p.S299_T318dup 
p.K304_Q305insL 
p.L315_E316insQ 
Classic N + C p30 + C-LOF 
Non-classic DM p.A44fs 
p.I68fs 
p.L78fs 
p.A295P 
p.R297P 
p.R300P 
Classic N + C-missense 
Classic N + C-missense 
Classic N + C-missense 
p30 + C-LOF 
 
 
 p.H24fs 
p.H24fs 
p.G36fs 
p.G38fs 
p.G54fs 
p.V95fs 
p.Q209fs 
p.G233fs 
p.Y181X 
p.K313fs 
p.E167fs 
p.A238fs 
Classic N + mid-frameshift 
Classic N + mid-frameshift 
Classic N + mid-nonsense 
Classic N + C-frameshift 
Classic N + mid-frameshift 
Classic N + mid-frameshift 
p30 + null 
 p.R300_D301delinsQN (Hom) 
p.E316_R325dup (Hom) 
p.N321S (Hom) 
p.L317Q (Hom) 
p.R306_V314dup 
 
 
 
 
p.N321S 
Classic C 
Classic C 
C-missense 
C-missense 
Classic C + C-missense 
C-LOF 
SM p.P23fs 
p.H24fs 
p.P46fs 
p.E59X 
p.T60fs 
p.S61fs 
p.A66fs 
p.I68fs 
p.Q83fs 
 Classic N p30 + WT 
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M2 
(cont) 
p.R300_D301delinsQY 
p.K313dup (x 2) 
p.R323del 
p.N356_C357del 
 Classic C C-LOF + WT 
p.G122fs 
p.G123fs 
p.E166X 
p.D168fs 
p.P180fs 
p.Q215X 
p.L253fs 
p.S266fs 
p.K275fs 
 Mid-frameshift/nonsense Null + WT 
p.N292fs 
p.N307fs 
 C-frameshift Null + WT 
p.Y285S 
p.R289C 
p.V296E 
p.L331Q 
p.I341V 
 C-missense C-LOF + WT 
p.P187_P189del 
p.H193_P196del 
p.P239_A240del 
 Mid-indel UNK + WT 
p.P183Q 
p.P233R 
p.G242S (x 2) 
p.K276R 
 Mid-missense UNK + WT 
	Null	indicates	mid-region	or	C-terminal	mutants	with	a	truncating	frameshift	or	nonsense	mutation.	Abbreviations:	C,	C-terminal	mutation;	Clin,	Clinical	cohort;	Coh,	cohort;	DM,	double	CEBPA	mutant;	del,	deletion;	dupl,	duplication;	fs,	frameshift;	Hom,	homozygous;	indel,	insertion/deletion;	ins,	insertion;	LOF,	loss-of-function;	M1,	Methylation	cohort	1;	M2,	Methylation	cohort	2;	Mid,	mid-region;	N,	N-terminal	mutation;	SM,	single	CEBPA	mutant;	UNK,	unknown;	WT,	wild-type			 	
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Table	S2.	Demographic	details	of	the	104	patients	in	the	clinical	analysis		Parameter	 Classic	CEBPADM	(n=79)	 Non-classic	CEBPADM	(n=25)	 P*	Median	age,	years	(IQR)	 35	(25	to	46)	 47	(42	to	55_	 0.001**	Median	WBC,	x109/L	(IQR)	 27.6	(10.5-67.4)	 15.9	(7.7-92.9)	 0.7**	Sex:						Male						Female	 	44	(56%)	35	(44%)	 	15	(60%)	10	(40%)	 0.8	Trial:						AML10						AML12						AML15	
	16	(21%)	31	(39%)	32	(41%)	
	6	(24%)	11	(44%)	8	(32%)	
0.7	
WHO	Performance	status:						0						1						2						3	
	55	(70%)	11	(14%)	12	(15%)	1	(1%)	
	13	(52%)	8	(32%)	3	(12%)	1	(4%)	
0.1	
AML	type:						De	novo						Secondary	 	77	(97%)	2	(3%)	 	25	(100%)	0	(0%)	 1.0	Transplant	status:						No	transplant						Allograft						Autograft						Other	
	48	(61%)	19	(24%)	9	(11%)	3	(4%)	
	14	(56%)	7	(28%)	4	(16%)	0	(0%)	
0.8	
Stage	of	transplant:						First	remission						First	relapse						Second	remission	
	18	(58%)	1	(3%)	12	(39%)	
	6	(55%)	1	(9%)	4	(36%)	
0.7	
Cytogenetics:						FR						IR											NK											AK						AR						No	result	
	0	(0%)	68	(100%)						53	(78%)						15	(22%)	0	(0%)	11		
	1	(5%)	17	(89%)						12	(63%)							5	(26%)	1	(5%)	6	(24%)	
0.05	
FLT3ITD	
NPM1MUT	
DNMT3AMUT
IDH1MUT	
IDH2MUT	
WT1MUT	
TET2MUT	
GATA2MUT	
8	(10%)	2	(3%)	2/76	(3%)	0/60	(0%)	1	(1%)	7/71	(10%)	3/30	(10%)	28/72	(39%)	
1	(4%)	1	(4%)	4	(16%)	1/21	(5%)	5	(20%)	0/20	(0%)	5/18	(28%)	4/23	(17%)	
0.7	0.6	0.03	0.3	0.003	0.3	0.1	0.1			*P	values	are	Fishers	exact	test	unless	otherwise	stated;	**Wilcoxon	rank	sum	test	Abbreviations:	AK,	intermediate-risk	abnormal	karyotype;	AR,	adverse	risk;	FR,	favorable	risk;	IQR,	interquartile	range;	IR,	intermediate	risk;	NK,	normal	karyotype;	WBC,	white	blood	cell	count			
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Table	S3.	 The	top	25	most	differentially	methylated	sites	between	CEBPAClassic-DM	and	CEBPAWT	samples.	The	probes	were	selected	by	Wilcoxon	tests	and	the	median	difference	between	the	samples	(mean	rank	of	both	parameters)	and	are	ordered	by	their	median	beta	value	in	
CEBPAClassic-DM	samples.		
	
	
!Probe!ID Chr Position
Dist.!
to!TSS ENSEMBL!Gene!ID Symbol Description
In!CpG!
Island
WT!
Median!β
Classic!DM!
Median!β
Wilcoxon!
PAvalue
Median!
∆ Rank
cg21237418 17 24069170 ,157 ENSG00000109113 RAB34 RAB34,6member6RAS6oncogene6family FALSE 0.153 0.928 4.91E,07 0.775 2
cg14338887 6 43036478 0 ENSG00000124713 GNMT Glycine6N,methyltransferase TRUE 0.170 0.918 3.93E,06 0.748 3
cg17186163 10 44794323 7 ENSG00000165507 C10orf10 Chromosome6106open6reading6frame610 FALSE 0.155 0.907 4.09E,08 0.752 1
cg24101359 6 43036473 5 ENSG00000124713 GNMT Glycine6N,methyltransferase6 TRUE 0.199 0.904 1.89E,05 0.705 20
cg13105904 14 23969884 ,903 ENSG00000100441 KHNYN KH6and6NYN6domain6containing TRUE 0.306 0.889 5.56E,06 0.583 10
cg01274660 7 100303561 ,675 ENSG00000087077 TRIP6 Thyroid6hormone6receptor6interactor66 FALSE 0.317 0.888 1.80E,05 0.572 25
cg04355435 1 43508877 117 ENSG00000179178 TMEM125 Transmembrane6protein6125 FALSE 0.349 0.879 7.69E,06 0.531 22
cg10056627 6 43036751 ,273 ENSG00000124713 GNMT Glycine6N,methyltransferase TRUE 0.249 0.877 1.42E,05 0.629 16
cg27588902 6 43036129 349 ENSG00000124713 GNMT Glycine6N,methyltransferase TRUE 0.265 0.854 2.74E,06 0.589 4
cg25651505 2 85665534 ,492 ENSG00000168899 VAMP5 Vesicle6associated6membrane6protein65 TRUE 0.347 0.837 2.74E,06 0.489 18
cg23696834 6 43036323 155 ENSG00000124713 GNMT Glycine6N,methyltransferase6 TRUE 0.102 0.822 3.93E,06 0.720 5
cg24081819 8 27404857 ,295 ENSG00000120915 EPHX2 Epoxide6hydrolase62,6cytoplasmic TRUE 0.243 0.817 3.93E,06 0.574 9
cg08965235 11 65081734 541 ENSG00000168056 LTBP3 Latent6TGF6beta6binding6protein63 TRUE 0.266 0.804 2.74E,06 0.538 11
cg16068833 1 26517102 ,104 ENSG00000169442 CD52 CD526molecule FALSE 0.227 0.763 1.06E,05 0.536 24
cg19764555 11 62071695 ,787 ENSG00000124942 AHNAK AHNAK6nucleoprotein TRUE 0.272 0.763 2.74E,06 0.491 17
cg00350296 11 65841417 ,343 ENSG00000174807 CD248 CD2486molecule,6endosialin FALSE 0.253 0.738 2.74E,06 0.485 19
cg10798171 7 8268826 ,59 ENSG00000003147 ICA1 Islet6cell6autoantigen61 TRUE 0.249 0.715 4.09E,08 0.466 13
cg15032239 15 20443395 709 ENSG00000068793 CYFIP1 Cytoplasmic6FMR16interacting6protein61 TRUE 0.195 0.708 4.09E,08 0.513 6
cg16155382 1 24518778 ,135 ENSG00000158055 GRHL3 Grainyhead,like6transcription6factor636 FALSE 0.101 0.678 3.69E,06 0.577 8
cg13490971 5 141468305 203 ENSG00000131507 NDFIP1 Nedd46family6interacting6protein61 TRUE 0.203 0.653 4.09E,08 0.450 14
cg21697134 17 78287128 ,331 ENSG00000167363 FN3K Fructosamine636kinase FALSE 0.090 0.614 1.04E,07 0.524 7
cg08897388 6 112682398 44 ENSG00000112769 LAMA4 Laminin6subunit6alpha64 TRUE 0.135 0.575 1.84E,06 0.440 23
cg12417466 3 35658823 30 ENSG00000172995 ARPP21 CAMP6regulated6phosphoprotein621kDa FALSE 0.720 0.179 5.56E,06 ,0.541 15
cg05615150 3 35658819 34 ENSG00000172995 ARPP21 CAMP6regulated6phosphoprotein621kDa FALSE 0.668 0.113 5.56E,06 ,0.555 12
cg18920397 1 159032429 123 ENSG00000122224 LY9 Lymphocyte6antigen69 FALSE 0.625 0.071 1.06E,05 ,0.554 21
Genomic!Location Gene Signature!Details
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Table	S4.	Details	of	primers	and	conditions	for	methylation-specific	PCR	and	pyrosequencing	assays.			 Gene	 Primer	 Primer	Sequence	 Size	(bp)	 Annealing	Temp	(oC)	Methylation-specific	PCR	for	bisulfite	conversion	 HLA-B	converted		
HLA-B	unconverted	 F	R	F	R	
5’-TTTTAAGTTTTATTTTTGTGGGGTA-3’	5’-AAATCCCAACTAATAACTATTTTTCAA-3’	5’-CCCAAAGTCCACTAACATTAGAA-3’	5’-GCTGAGAAAATAGCCTCAGAATA-3’	
300		464	 Touchdown	(see	text)	Touchdown	(see	text)	Pyrosequencing	assays	for	array	validation	 SOCS2		
	
WNT2		
	
PRF1	A		
	
PRF1	B	
F	(biotinylated)	R	Sequencing	F	R	(biotinylated)	Sequencing	F	R	(biotinylated)	Sequencing	F	R	(biotinylated)	Sequencing	
5’-AGGTGGGAAGTAAAGAATAAGATGGA-3’	5’-CCAAACCTAAATCCCTAAAAAACCACTTT-3’	5’-CCTAAAAAACCACTTTCCT-3’	5’-GTGTATGAAATGATGGTAAGAGATGTT-3’	5’-ATACATAATAATCTCCTTATCCCCTAACC-3’	5’-GGGAAGGGGGAATATYGTTGTATG-3’	5’-AGTAGGGTTATTTTTTTGTTTTTGATGT-3’	5’-CCTACCAATCCACACTACTAATACA-3’	5’-GTTATTTTTTTGTTTTTGATGTATA-3’	5’-TAGGAAGTGTTGTGATTTATAAGATAAG-3’	5’CTTTAATATCAACACTTACAAAACCTTAA-3’	5’-TAAGATAAGATATTTGGGTTA-3’	
128			246			150			163	
62			62			60			60	
Pyrosequencing	assays	for	good-risk	patients	 LY9		
	
KHNYN		
	
VAMP5		
F	(biotinylated)	R	Sequencing	F	(biotinylated)	R	Sequencing	F	R	(biotinylated)	Sequencing	
5’-TGTTTTAGAGGGAGGGTTGTTTATA-3’	5’-AATCACAAATAAAACCCTAAATAAACTTA-3’	5’-TAAAACCTCTACCTACC-3’	5’-GGGTTTTTTAGTTGTAGTTAGATGTG-3’	5’-ACTAAAAACAACAACCATACCTAC-3’	5’-ACCCCATATAAAACCCATCTTC-3’	5’-GTGTTYGTTTATTAGGTAGAGGTGTTA-3’	5’-CCCRCCTAAACCCTCACCATC-3’	5’-	GTTTATYGTTTTYGATTTGATTTGG-3’	
100			192			281	
58			60			59	
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SUPPLEMENTARY	FIGURES		
Figure	S1.		Flowchart	showing	the	patients	investigated	in	the	different	analyses	performed.	
	
	
2162$pa'ents$entered$into$the$UK$MRC$AML10,$12$
and$15$trials$with$known$CEBPA$genotype$
1984$(92%)$$
CEBPAWT$
74$(3%)$$
CEBPASM$
104$(5%)$$
CEBPADM$
79$(76%)$$
Classic$CEBPADM$
25$(24%)$$
NonNclassic$CEBPADM$
79$
Outcome$analysis$$
25$
Outcome$analysis$$
56$
Methyla'on$
analysis$
30$cohort$1$
26$cohort$2$
38$
Methyla'on$
analysis$
All$cohort$2$
25$
Methyla'on$
analysis$
8$cohort$1$
17$cohort$2$
$
16$
Methyla'on$
analysis$
2$cohort$1$
14$cohort$2$
	 11	
Figure	S2.		Comparison	of	methylation	quantification	values	obtained	at	four	CpG	sites	investigated	on	the	arrays	and	by	
pyrosequencing	using	the	preliminary	set	of	40	samples.	(a-d)	b	values	obtained	from	the	methylation	array	versus	%	methylation	by	pyrosequencing.	(e-h)	Bland-Altman	plots	showing	the	mean	result	for	each	sample	compared	with	the	difference	in	values	between	the	two	assays.	The	dotted	line	indicates	the	95%	confidence	intervals	for	each	probe.	Details	of	PCR	primers	and	assay	conditions	are	given	in	Table	S4.					
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(b) WNT2
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Figure	S3.	Unsupervised	cluster	analysis	of	the	follow-up	cohort.	Each	column	represents	a	patient.	Genotype	is	given	in	the	upper	panel.	Samples	were	clustered	based	on	their	methylation	levels	at	157,797	variable	probes	and	the	heatmap	in	the	middle	panel	shows	the	variable	CpG	probes	located	within	CGIs.	The	latter	were	used	to	calculate	the	mean	%	CpG	methylation	shown	in	the	lower	panel;	red	and	blue	bars	indicate	a	predominantly	hyper-	or	hypo-methylated	profile	respectively.			
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Figure	S4.	Methylation	levels	in	other	good-risk	groups	compared	to	the	CEBPAClassic-DM	cases	at	three	differentially	methylated	CpG	
sites.	The	24	CEBPAClassic-DM	(excluding	the	outlier)	and	56	CEBPAWT	results	were	beta	values	from	the	arrays;	results	for	the	three	comparative	groups	were	obtained	by	pyrosequencing.	Significance	refers	to	difference	from	the	CEBPAClassic-DM	group	(*P≤0.05,	**P≤0.01,	***P≤0.001)				
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